News Releases

News & Resources

News Releases

ECCRT, a Synteract Company, Recognized as an Accredited Training Facility by TransCelerate BioPharma Inc.

European Centre for Clinical Research Training meets standards established by association of biopharma companies

SAN DIEGO – April 8, 2014 – The European Centre for Clinical Research Training (ECCRT), a Synteract company, has been recognized by TransCelerate BioPharma Inc, as an official training facility that meets the standards established for investigator training by this association of biopharma companies.

TransCelerate BioPharma Inc. is a non-profit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges, and further improving patient safety, with the goal of delivering more high quality medicines to patients. It has established several clinical data standards, including study site qualification and training. Once accredited by the organization, ECCRT is recognized by all members of the organization as an approved training facility for investigators – which in turn, means that all investigators trained by this facility meet the standards established.

“Synteract and its training facility are dedicated to supporting even higher levels of proficiency in the industry,” says Gerald Van Roey, M.Ph.Ed., managing director at ECCRT. “To achieve this end, it was imperative for us to be acknowledged as an industry-recognized site for investigator training. Training is an important investment for companies, and one that will pay off in the long-run, in having both more engaged employees and better patient care.”

TransCelerate evolved from discussions at various forums for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. Synteract supports the goal of this organization to enhance focus on qualitative training based on good course design, correct methodology and Good Clinical Practice. As part of its ICD+ initiative, Synteract seeks out ways to increase efficiencies, streamline process and improve outcomes; ECCRT’s recognition by TransCelerate meets the goals of the organization as well as that of its parent company.

About Synteract
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.

CONTACT:
Beth Walsh
beth@clearpointagency.com
760-230-2424

x

Contact Synteract

Tell us how to stay in touch with you:

*Required